Physician profile
Robert E Khalil
NPI 1205083359
$3,647.58
in general payments reported to CMS, 2019-2025
28 companies · $769 in 2025
The $769 reported for 2025 was more than what 82% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $90.12 · 2021: $375 · 2022: $379 · 2023: $995 · 2024: $861 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $618.02 | 2022-2025 | Caplyta |
| Lundbeck LLC | $529.58 | 2021-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $347.26 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $288.90 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $263.23 | 2023-2025 | Auvelity |
| Corium, LLC | $232.95 | 2022-2024 | Azstarys |
| Arbor Pharmaceuticals, INC. | $168.49 | 2019-2021 | |
| Abbvie INC. | $151.88 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $145.81 | 2020-2025 | Uzedy |
| Adlon Therapeutics L.P. | $97.82 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $96.40 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $82.21 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $75.90 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $69.86 | 2022-2024 | Rexulti |
| Indivior INC. | $63.84 | 2019-2025 | Sublocade |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $58.82 | 2023 | Spravato, Invega Trinza, Invega Sustenna |
| Shire North American Group INC | $42.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.40 | 2020 | |
| Avanir Pharmaceuticals, INC. | $39.36 | 2022 | |
| Alkermes, INC. | $38.99 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $35.42 | 2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $31.20 | 2021 | |
| Antares Pharma, INC. | $30.74 | 2024 | Xyosted |
| Azurity Pharmaceuticals, INC. | $23.91 | 2023 | Horizant |
| Acerus Pharmaceuticals Corporation | $23.86 | 2022 | |
| Neos Therapeutics, LP | $21.52 | 2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $16.03 | 2023 | Loreev Xr, Sertraline Hcl |
| Orexo US, INC. | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.